Human papillomaviruses in non-melanoma skin cancer

Seminars in Cancer Biology

Volumn 9, Issue 6, 1999, Pages 413-422

  De Villiers, Ethel Michele ^a   Ruhland, Astrid ^a   Šekaric, Pedja ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytokines; HPV; Skin cancer; UV

Indexed keywords

CYTOKINE; PROTEIN P53; TUMOR PROMOTER;

CYTOKINE RELEASE; DNA DAMAGE; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE DELETION; GENE EXPRESSION; HUMAN; NONHUMAN; REVIEW; SEQUENCE HOMOLOGY; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; WART VIRUS;

EID: 0033504609     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1999.0145     Document Type: Article

References (115)

1. Stern RS. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol. 135:1999;843-844.
2. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol. 30:1994;774-748.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics. CA Cancer J Clin. 65:1996;5-27.
4. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 131:1994;455-464.
5. Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol. 135:1999;781-786.
6. Gailani MR, Bale AE. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst. 89:1997;1103-1109.
7. Majewski S, Jablonska S. Skin autographs in Epidermodysplasia verruciformis: Human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res. 57:1997;4214-4216.
8. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 protein. J Virol. 66:1992;5100-5105.
9. Medcalf EA, Milner J. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+@ml04 p53 conformation. Oncogene. 8:1993;2847-2851.
10. Scheffner M, Werness BA, Huibregtse JM, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
11. Li X, Coffino P. High-risk papillomavirus E6 protein has two dis tinct binding sites within p53, of which only one determines degradation. J Virol. 70:1996;4509-4516.
12. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Pontén J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 88:1991;10124-10128.
13. Ziegler A, Jonasen AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remongton L, Jacks T, Brash DE. Sunburn and p53 in the onset of skin cancer. Nature. 372:1994;773-776.
14. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA. 90:1993;4216-4220.
15. Ren ZP, Pontén F, Nister M, Pontén J. Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer. 69:1996;174-179.
16. Pfeifer GP, Holmquist GP. Mutagenesis in the p53 gene. Biochim Biophys Acta. 1333:1997.
17. Ouhtit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, Yamasaki H, English DR. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst. 90:1998;523-531.
18. Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen+UVA (PUVA). J Invest Dermatol. 109:1997;238-243.
19. Gu Z, Pim D, Labrecque S, Banks L, Matlashewski G. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene. 9:1994;629-633.
20. Kiyono T, Hiaiwa A, Ishii S, Takahashi T, Ishibashi M. Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin. J Virol. 68:1994;4656-4661.
21. Purdie KJ, Pennington J, Proby CM, Khalaf S, de Villiers E-M, Leigh IM, Storey A. The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. EMBO J. 18:1999;5359-5369.
22. Ren Z-P, Hedrum A, Pontén F, Nister M, Ahmadian A, Lundeberg J, Uh lén M, Pontén J. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene. 12:1996;765-773.
23. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA. 93:1996;14025-14029.
24. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 7:1987;961-963.
25. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393:1998;229-234.
26. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumor-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13:1994;3496-3504.
27. Levine AJ. The tumor suppressor genes. Annu Rev Biochem. 62:1993;623-651.
28. Ahmadian A, Ren ZP, Williams C, Pontén F, Odeberg J, Pontén J, Uhlen M, Lundeberg J. Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma. Oncogene. 17:1998;1837-1843.
29. WAF1/CIP1protein in keratinocytes without p53. J Invest Dermatol. 113:1999;283-284.
30. Rehman I, Takata M, Wu Y-Y, Rees JL. Genetic alterations in actinic keratoses. Oncogene. 12:1996;2483-2490.
31. WAF1/CIP1enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res. 59:1999;2050-2054.
32. WAF1/CIP1in UV-irradiated and transformed cells. Oncogene. 16:1998;1333-1343.
33. CDKN2Aexpression in human skin. Cancer Res. 59:1999;4185-4189.
34. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1378:1998.
35. Soufir N, Moles JP, Vilmer C, Moch C, Verola O, Rivet J, Tesniere A, Dubertret L, Basset-Seguin N. P16 UV mutations in human skin epithelial tumors. Oncogene. 18:1999;5477-5481.
36. Kripke ML. Effects of UV radiation on tumor immunity. J Natl Cancer Inst. 82:1990;1392-1396.
37. Streilein JW, Taylor JR, Vincek V, Kurimoto I, Richardson J, Tie C, Medema J-P, Golomb C. Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J Invest Dermatol. 103:1994;107.
38. Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet. 337:1991;211-214.
39. Lee HS, Kooshesh F, Sauder DN, Kondo S. Modulation of TGF-beta 1 production from human keratinocytes by UVB. Exp Dermatol. 6:1997;105-110.
40. Kirnbauer R, Kock A, Neuner P, Porster E, Krutmann J, Urbanski A, Schauer E, Ansel JC, Schwarz T, Luger TA. Regulation of epidermal cell interleukin-6 production by UV light and corticosteroids. J Invest Dermatol. 96:1991;484-489.
41. Yarosh DB, Kripke ML. DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Mutat Res. 350:1996;255-260.
42. Petit-Frère C, Clingen PH, Grewe M, Krutmann J, Roza L, Arlett CF, Green MHL. Induction of interleukin-6 production by ultraviolet radiation in normal human epidermal keratinocytes and in a human keratinocyte cell line is mediated by DNA damage. J Invest Dermatol. 111:1998;354-359.
43. Barr RM, Walker SL, Tsang W, Harrison GI, Ettehadi P, Greaves MW, Young AR. Suppressed alloantigen presentation, increased TNF-a, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin. J Invest Dermatol. 112:1999;692-698.
44. Corsini E, Sangha N, Feldman SR. Epidermal stratification reduces the effects of UVB (but not UVA) on keratinocyte cytokine production and cytotoxicity. Photodermatol Photoimmunol Photomed. 13:1997;147-152.
45. Kondo S, Sauder DN, Kondo T, Galley KA, McKenzie RC. Differential modulation of interleukin-1a (IL-1a) and interleukin-1β (IL-1β) in human epidermal keratinocytes by UVB. Exp Dermatol. 3:1994;29-39.
46. Leverkus M, Yaar M, Eller MS, Tang EH, Gilcrest BA. Post-transcriptional regulation of UV induced TNF-a expression. J Invest Dermatol. 110:1998;353-357.
47. Dissanayake NS, Mason RS. Modulation of skin cell functions by transforming growth factor-beta1 and ACTH after ultraviolet irradiation. J Endocrinol. 159:1998;153-163.
48. Norris DA, Travers JB, Leung DYM. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol. 109:1997;1-4.
49. Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S. Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol. 110:1998;311-317.
50. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta. 1288:1996.
51. zur Hausen H. Papillomaviruses causing cancer: The evasion from host cell control marks early events in carcinogenesis. J Natl Cancer Inst, 1999.
52. Braun L, Dürst M, Mikumo R, Grupposo P. Differential response of non-tumorigenic and tumorigenic human papillomavirus type 16 positive epithelial cells to transforming growth factor β Cancer Res. 50:1990;7324-7332.
53. Woodworth CD, Notario V, DiPaolo JA. Transforming growth factor beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human epithelial cells. J Virol. 64:1990;4767-4775.
54. Malejczyk J, Malejczyk M, Köck A, Urbanski A, Majewski N, Hunzelma nn N, Jablonska S, Orth G, Luger TA. Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-α J Immunol. 149:1992;2702-2708.
55. Rösl F, Lengert M, Albrecht J, Kleine K, Zawatsky R, Schraven B, z ur Hausen H. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol. 68:1994;2142-2150.
56. de Geest K, Bergman CA, Turyk ME, Frank BS, Wilbanks GD. Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-beta 1. Gynecol Oncol. 55:1994;376-385.
57. Braun L, Dürst M, Mikumo R, Crowley A, Robinson M. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection. Mol Carcinogen. 6:1992;100-111.
58. Woo KM, Lee G, Kook JK, Min BM. Conversion of normal human oral keratinocytes to tumorigenic cells is associated with the acquisition of resistance to TGF-beta. Int J Oncol. 12:1998;833-839.
59. Woodworth CD, Chung J, McMullin E, Plowman GD, Simpson S, Iglesias M. Transforming growth factor beta 1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation. Cell Growth Differ. 7:1996;811-820.
60. Ozbun MA, Meyers C. Transforming growth factor beta 1 induces differentiation in human papillomavirus-positive keratinocytes. J Virol. 70:1996;5437-5446.
61. Mota F, Rayment N, Chong S, Singer A, Chain B. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol. 116:1999;33-40.
62. Hagari Y, Budgeon LR, Pickel MD, Kreider JW. Association of tumor necrosis factor-alpha gene expression and apoptotic cell death with regression of Shope papillomas. J Invest Dermatol. 104:1995;526-529.
63. Kyo S, Inoue M, Hayasaka N, Inoue T, Yutsudo M, Tanizawa O, Hakura A. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology. 200:1994;130-139.
64. Iglesias M, Yen K, Gaiotti D, Hildesheim A, Stoler MH, Woodworth CD (. uman papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1alpha. Oncogene. 17:1998;1195-1205.
65. Malejczyk M, Jozwiak J, Osiecka A, Roszkowski PI, Mazurkiewicz-Smoktunowicz W, Rogozinski TT, Walczak L, Jablonska S, Majewski S, Malejczyk J. Serum levels of soluble tumor-necrosis-factor receptors in patients with benign and malignant HPV-associated anogenital lesions. Int J Cancer. 73:1997;16-19.
66. Woodworth CD, McMullin E, Iglesias M, Plowman GD. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci USA. 92:1995;2840-2844.
67. Merrick DT, Winberg G, McDougall JK. Re-expression of interleukin 1 in human papillomavirus 18 immortalized keratinocytes inhibits their tumorigenicity in nude mice. Cell Growth Differ. 7:1996;1661-1669.
68. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R, Rösl F. Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer. 82:1999;6-11.
69. Bryan D, Sexton CJ, Williams D, Leigh IM, McKay IA. Oral keratinocytes immortalized with the early region of human papillomavirus type 16 show elevated expression of interleukin 6, which acts as an autocrine growth factor for the derived T103C cell line. Cell Growth Differ. 6:1995;1245-1250.
70. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol. 146:1995;944-952.
71. Tjiong MY, van der Vange N, ten Kate FJ, Zjong-A-Hung SP, ter Schegget J, Burger MP, Out TA. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 73:1999;285-291.
72. Kuhn C, Hurwitz SA, Kumar MG, Cotton J, Spandau DF. Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation. Int J Cancer. 80:1999;431-438.
73. de Villiers E-M. Human papillomavirus infections in skin cancers. Biomed Pharmacother. 52:1998;26-33.
74. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol. 133:1997;1263-1270.
75. Orth G. Epidermodysplasia verruciformis: a model for understand ing the oncogenicity of human papillomaviruses. Ciba Found Symp. 120:1986;157-174.
76. Jablonska S, Majewski S. Epidermodysplasia verruciformis: Immun ological and clinical aspects. Curr Top Microbiol Immunol. 186:1994;157-175.
77. de Villiers E-M. Human pathogenic papillomavirus types: An update. Curr Topics Microbiol Immunol. 186:1994;1-12.
78. Inaba Y, Egawa K, Yoshimura K, Ono T. Demonstration of human papillomavirus type 1 DNA in a wart with bowenoid changes. Am J Dermatopathol. 15:1993;172-175.
79. Noel JC, Detremmerie O, Peny MO, Candaele M, Verhest A, Heenen M, de Dobbeleer G. Transformation of common warts into squamous cell carcinoma on sun-exposed areas in an immunosuppressed patient. Dermatology. 189:1994;308-311.
80. de Villiers E-M, Lavergne D, McLaren K, Benton EC. Prevailing pa pillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer. 73:1997;356-361.
81. de Villiers E-M. Papillomavirus and HPV typing. Clin Dermatol. 15 : 1997;199-206.
82. de Villiers E-M. Importance of human papillomavirus DNA typing in the diagnosis of anogential warts in children. Arch Dermatol. 131:1995;366-367.
83. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, zur Hausen H, de Villiers E-M. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res. 54:1994;4610-4613.
84. Surentheran T, Harwood CA, Spink PJ, Sinclair AL, Leigh IM, Proby CM, McGregor JM, Breuer J. Detection and typing of human papillomaviruses in mucosal and cutaneous biopsies from immunosuppressed and immunocompetent patients and patients with epidermodysplasia verruciformis: a unified diagnostic approach. J Clin Pathol. 51:1998;606-610.
85. Harwood CA, Spink PJ, Surentheran T, Leigh IM, Hawke JLM, Proby CM, Breuer J, McGregor JM. Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol. 111:1998;123-127.
86. Ohnishi T, Kano R, Nakamura Y, Hasegawa A, Watanabe S. Genital Bowen disease associated with an unusual human papillomavirus type HPV 57b. Arch Dermatol. 135:1999;858-859.
87. Obalek S, Favre M, Szymanczyk J, Misiewicz J, Jablonska S, Orth G. Human papillomavirus (HPV) types specific for epidermodysplasia verruciformis detected in warts induced by HPV 3 and HPV 3-related types in immunosuppressed patients. J Invest Dermatol. 98: 1992;936-941.
88. Delius H, Saegling B, Bergmann K, Shamanin V, de Villiers E-M. The genomes of three of four novel HPV types, defined by differences of their L1 genes, show high conservation of the E7 gene and the URR. Virology. 240:1998;359-365.
89. Pennington, J, Clayson, S, de Villiers, E-M, Proby, C, Leigh, I, M, Storey, A. Transforming and biochemical properties of the HPV 77 E7 protein, a novel papillomavirus isolated from a renal transplant recipient
90. Scheurlen W, Gissmann L, Gross G, zur Hausen H. Molecular cloning of two new HPV types (HPV 37 and HPV 38) from a kerato-acanthoma and a malignant melanoma. Int J Cancer. 37:1986;505-510.
91. Boxman ILA, Berkhout RJM, Mulder LHC, Wolkers MC, Bouwes Bavinck JN, Vermeer BJ, ter Schegget J. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol. 108:1997;712-715.
92. Boxman ILA, Hogewoning A, Mulder LHC, Bouwes Bavinck JN, ter Schegget, J. Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts. J Clin Microbiol. 37:1999;2270-2273.
93. Astori G, Lavergne D, Benton C, Höckmayr B, Egawa K, Garbe C, de Villiers E-M. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol. 110:1998;752-755.
94. Weissenborn SJ, Hopfl R, Weber F, Smola H, Pfister HJ, Fuchs PG. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol. 113:1999;122-126.
95. Kawashima M, Favre M, Obalek S, Jablonska S, Orth G. Premalignant lesions and cancers of the skin in the general population: Evaluation of the role of human papillomaviruses. J Invest Dermatol. 95:1990;537-542.
96. de Jong-Tieben LM, Berkhout RJM, Smits HL, Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, ter Schegget J. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol. 105:1995;367-371.
97. Harris AJ, Purdie K, Leigh IM, Proby C, Burge S. A novel human papillomavirus identified in epidermodysplasia verruciformis. Br J Dermatol. 136:1997;5.
98. Höpfl R, Bens G, Wieland U, Petter A, Zelger B, Fritsch P, Pfister H. Human papillomavirus DNA in non-melanoma skin cancers of a renal transplant recipient: Detection of a new sequence related to epidermodysplasia verruciformis associated types. J Invest Dermatol. 108:1997;53-56.
99. Maurer TA, Christian KV, Kerschmann RL, Berzin B, Palefsky JM, Payne D, Tyring SK, Berger TG. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol. 133:1997;577-583.
100. Wieland U, Gross GE, Hofmann A, Sohendra N, Berlien HP, Pfister H. Novel human papillomavirus (HPV) DNA sequences from recurrent cutaneous and mucosal lesions of a stoma-carrier. J Invest Dermatol. 111:1998;164-168.
101. de Villiers, Kiviat, Koutsky
102. Jablonska S, Obalek S, Favre M, Golebiowska A, Croissant O, Orth G. The morphology of butchers' warts as related to papillomavirus types. Arch Dermatol Res. 279:1987.
103. Greenspan D, de Villiers E-M, Greenspan JS, de Souza YG, zur Hausen H. Unusual HPV types in oral warts in association with HIV infection. J Oral Pathol. 17:1988;482-487.
104. de Villiers E-M. Prevalence of HPV 7 papillomas in the oral mucosa and facial skin of patients with human immunodeficiency virus. Arch Dermatol. 125:1989;1590.
105. Hirt L, Hirsch-Behnam A, de Villiers E-M. Nucleotide sequence of human papilomavirus (HPV) type 41: an unusual HPV type without a typical E2 binding site consensus sequence. Virus Res. 18:1990;179-190.
106. Shamanin V, zur Hausen H, Lavergne D, Proby CM, Leigh IM, Neumann C, Hamm H, Goos M, Haustein U-F, Jung EG, Plewig G, Wolff H, de Villiers E-M. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and non-immunosuppressed patients. J Natl Cancer Inst. 88:1996;802-811.
107. Boshart M, Klueppel M, Schmidt A, Schuetz G, Luckow ZH. CAT reporter constructs with low background activity. Gene. 110:1992;129-130.
108. Stein B, Krämer M, Rahmsdorf HJ, Ponta H, Herrlich P. UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells. J Virol. 63:1989;4540-4544.
109. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinogenesis. 23:1998;144-158.
110. Chaturvedi V, Qin J-Z, Denning MF, Choubey D, Diaz MO, Nickoloff BJ (. poptosis in proliferating, senescent, and immortalized keratinocytes. J Biol Chem. 33:1999;23358-23367.
111. Van Hogerlinden M, Rozell BL, Ährlund-Richter L, Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/Nuclear factor-kB signaling. Cancer Res. 59:1999;3299-3303.
112. Kumar S, Orsini MJ, Lee JC, McDonnell PC, Debouck C, Young PR. Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase. J Biol Chem. 271:1996;30864-30869.
113. -/-keratinocytes. Int J Oncol. 13:1998;781-789.
114. Elekeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol Cell Biol. 19:1999;2594-2600.
115. Soto U, Das BC, Lengert M, Finzer P, zur Hausen H, Rösl F. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene. 18:1999;3187-3198.